Lolkema, Martijn P.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut

Pancreatic and Hepatic Oncology ResearchProteoglycans and glycosaminoglycans research

Cited by 1,120

Pan-cancer whole-genome analyses of metastatic solid tumours

Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2019) · Nature

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 1,106

The mutational footprints of cancer therapies

Pich, O., Muiños, F., Lolkema, M. P., Steeghs, N., Gonzalez-Perez, A., & Lopez-Bigas, N. (2019) · Nature Genetics

Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Cited by 309

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.

Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 129

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 76

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., et al. (2016) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 73

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer

Cancer-related Molecular PathwaysMelanoma and MAPK Pathways

Cited by 62

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 55

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: a proof-of-concept study

Peters, N. A., Constantinides, A., Ubink, I., van Kuik, J., Bloemendal, H. J., van Dodewaard, J. M., Brink, M. A., Schwartz, T. P., Lolkema, M. P. J. K., Lacle, M. M., et al. (2022) · Frontiers in Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 35

524P A Phase I, Open-Label, Dose-Escalation Trial of BI 1701963 in Patients (Pts) with KRAS Mutated Solid Tumours: A Snapshot Analysis

Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 34

Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Falchook, G. S., McKean, M., Kelly, W. K., Patel, M. R., Bupathi, M., Liaw, B. C.-H., Garmezy, B., Vuu, I., Smith, K., Gokani, P., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 17